
    
      This was a multicenter, randomized, double-blind, placebo-controlled trial of E5555, a PAR-1
      inhibitor. The total duration of individual study participation was 28 weeks (196 days). This
      included a treatment period of 24 weeks (168 days) and a follow-up period of 4 weeks (28
      days).
    
  